论文部分内容阅读
目的:回顾性分析细胞因子诱导的杀伤(CIK)细胞联合化疗治疗晚期胰腺癌患者的疗效及安全性。方法:搜集2010年9月至2016年2月就诊于郑州大学附属肿瘤医院生物免疫治疗科的28例晚期胰腺癌患者,这些患者接受吉西他滨和/或替吉奥化学药物治疗,在化疗结束1~3 d内回输体外培养的CIK细胞。观察指标为疾病进展(PD)率,疾病稳定(SD)率,部分缓解(PR)率,完全缓解(CR)率,中位生存期(mOS),6个月、12个月、18个月和24个月的生存率,疾病控制率(disease control rate,DCR)和不良反应。DCR包括CR、PR和SD。结果:28例患者中5例PR(17.86%),15例SD(53.57%),8例PD(28.57%),DCR为71.43%,mOS 15.41,6、12、18和24个月的生存率分别为85.71%、50.00%、39.28%和10.71%;主要不良反应为骨髓抑制、恶心、呕吐,给予对症处理后好转。结论:CIK细胞联合化疗是晚期胰腺癌患者安全、有效的治疗方法,患者不良反应小,耐受性良好,可显著延长患者生存时间。
Objective: To retrospectively analyze the efficacy and safety of cytokine-induced killer (CIK) cells combined with chemotherapy in patients with advanced pancreatic cancer. Methods: A total of 28 patients with advanced pancreatic cancer who were referred to the Department of Bioimmunotherapy of Cancer Hospital Affiliated to Zhengzhou University from September 2010 to February 2016 were enrolled in this study. These patients received gemcitabine and / In 3 d, CIK cells cultured in vitro were transfused. The observational indexes were disease progression (PD) rate, disease stability (SD) rate, partial remission rate, complete remission rate, median survival time, 6 months, 12 months and 18 months And 24-month survival, disease control rate (DCR) and adverse reactions. DCR includes CR, PR, and SD. Results: Among the 28 patients, 5 were PR (17.86%), 15 SD (53.57%), 8 PD (28.57%), DCR was 71.43%, mOS 15.41, 6,12,18 and 24 months Respectively, 85.71%, 50.00%, 39.28% and 10.71% respectively. The main adverse reactions were myelosuppression, nausea and vomiting, which were improved after symptomatic treatment. Conclusions: CIK cells combined with chemotherapy is a safe and effective treatment for patients with advanced pancreatic cancer. The patients have small adverse reactions and good tolerability, which can significantly prolong their survival time.